Dividend Calendar: Week of June 15, 2026

The week of June 15, 2026 presents dividend investors with a diverse array of income opportunities across multiple sectors. Fifteen notable companies are scheduled to go ex-dividend, offering yields ranging from 1.91% to 6.56%. This week’s lineup includes established dividend aristocrats, high-yielding telecommunications stocks, and reliable consumer staples that have consistently rewarded shareholders.

Ex-Dividend Stocks This Week

The following companies go ex-dividend during the week of June 15, 2026. Investors must own shares before the ex-dividend date to receive the upcoming dividend payment.

High-Yield Dividend Opportunities

Income-focused investors will find attractive yields among this week’s ex-dividend stocks. Pfizer leads with a 6.56% yield, reflecting both the pharmaceutical giant’s commitment to shareholder returns and current market conditions. Verizon follows closely at 5.75%, offering telecommunications sector exposure with reliable dividend coverage. AT&T rounds out the high-yield trio at 4.71%, continuing its focus on maintaining dividend payments despite recent business restructuring.

Bristol-Myers Squibb provides another compelling pharmaceutical option at 4.38%, while PepsiCo offers consumer staples exposure with a 3.98% yield. These higher-yielding opportunities come with varying risk profiles that investors should carefully evaluate alongside their income objectives.

Dividend Aristocrats and Blue-Chip Payers

Several dividend aristocrats and blue-chip companies feature in this week’s calendar, demonstrating the quality of available income investments. Johnson & Johnson, with its 2.18% yield and decades-long dividend growth streak, represents pharmaceutical sector stability. The Coca-Cola Company offers 2.49% with its legendary dividend consistency spanning multiple decades.

Procter & Gamble provides consumer goods exposure at 2.85%, while Chevron delivers energy sector income at 3.73%. These established dividend payers have historically demonstrated resilience through various economic cycles, making them attractive for long-term income portfolios. The combination of yield and dividend growth potential makes these stocks particularly appealing for investors seeking both current income and future purchasing power protection.

How to Use This Calendar

The ex-dividend date is the single most important column in the table above. To receive a dividend, an investor must own shares before the market opens on the ex-date. A common misconception is that buying on the ex-date itself qualifies you for the payment — it does not. U.S. equities settle on a T+1 cycle as of 2024, which means a trade executed on Monday, June 15 settles on Tuesday, June 16. Any purchase on the ex-date itself will not appear on the company’s books in time to capture the dividend.

The payment dates for the cash distribution listed as TBD will be confirmed in the 1-2 weeks leading up to each company’s earnings and dividend announcement cycle. Historically, large-cap dividend payers like Pfizer, Verizon, and AT&T declare on a quarterly cadence (typically late January, late April, late July, late October), and the cash payment follows roughly 4-6 weeks after the ex-date. Investors who already hold these positions at the start of the week will receive the indicated cash amounts automatically — no action is required.

Reading Yield Numbers Carefully

The yields shown in the table are trailing twelve-month yields calculated against the current share price, not the company’s forward guidance. This matters more than it might appear: a 6.56% indicated yield on Pfizer reflects the share price decline from its 2024 peak rather than an increase in absolute dividend dollars. If PFE were still trading near its 2024 high of $36, the same $1.72 annualized payout would imply a yield closer to 4.7%. Investors evaluating Pfizer as a yield play should confirm whether the dividend is covered by sustainable free cash flow — for a major pharmaceutical company with a mature drug pipeline, the answer is generally yes, but it is worth checking each company’s most recent 10-K filing rather than relying on the headline yield alone.

By contrast, lower yields in the 2-3% range (JNJ at 2.18%, GILD at 1.91%, WFC at 2.15%, KO at 2.49%) signal companies with more stable share prices where the dividend itself represents a smaller, but more predictable, slice of total return. For Japanese investors purchasing U.S. equities through most online brokers, these lower-yield names often behave more like a bond proxy within an equity allocation — useful for portfolio diversification but rarely worth buying purely for income. Gilead (GILD) is worth a particular note: its 1.91% yield is the lowest in the table, but GILD has aggressively grown its dividend over the last five years and sits in a defensive healthcare-biotech segment that behaves differently from pharma majors during a recession.

Why This Calendar Matters for Japanese Investors

U.S. dividend payments are subject to a statutory 30% withholding tax for non-resident investors, but the U.S.-Japan tax treaty reduces this to 15% for most account types, and to 10% for portfolio investors who properly document their status through a W-8BEN form filed with their broker. For Japanese retail investors holding U.S. equities through a domestic broker (SBI Securities, Monex, Rakuten Securities, etc.), the W-8BEN is typically submitted automatically during account setup — but it is worth confirming with the broker that the form is on file, since the moment a dividend payment is missed, the higher rate cannot be retroactively reclaimed for that quarter.

Japanese NISA accounts have an important wrinkle here. The Tsumitate枠 (accumulation account) is designed exclusively for diversified mutual funds and does not cover direct U.S. stock holdings. The Growth Investment枠 covers direct U.S. equities, with the annual contribution limit set at 3.6 million yen per calendar year as of 2026, and a lifetime tax-free ceiling on unrealized gains. Dividends received inside the NISA Growth Investment枠 are tax-free at the Japanese level. Capital gains from selling a U.S. stock held inside NISA are also tax-free, even if the eventual sale price reflects accumulated dividends that were reinvested.

For Japanese investors building a long-term portfolio, the practical workflow is: identify these U.S. dividend payers using KabuWire’s weekly calendar, then purchase through a NISA-eligible account where possible. The combination of the reduced 10% U.S. withholding rate plus NISA’s zero-tax treatment in Japan can compound meaningfully over a 5-10 year holding period, particularly for high-yield names like PFE, VZ, T, and BMY where the dividend dollars are large enough for FX swings to matter less than the absolute cash flow.

Currency Risk and Timing

Dividends are paid in U.S. dollars to Japanese holders, then converted to yen at the prevailing exchange rate on the payment date — not on the announcement date or the ex-date. For the week of June 15, 2026, the USD/JPY exchange rate was in the 142-146 range as markets digested Bank of Japan policy normalization and U.S. tariff-related uncertainty. Investors who received $1.72 per PFE share during this week’s payment cycle effectively received roughly 244-251 yen per share before Japanese tax treatment — a wider band than the headline dividend figure suggests.

This currency timing means that for Japanese investors, the “best” week to receive a USD dividend is when the yen is weakest relative to the dollar, even though the company’s payment schedule has nothing to do with FX markets. Over a 12-quarter holding period, FX swings of 5-10% can erase or double the effective yield in yen terms, which is one reason most Japanese advisors recommend treating U.S. dividend payers as a hybrid equity-currency position rather than a pure income play. Dollar-cost averaging the position size rather than committing all at once is one practical way to smooth this currency risk without abandoning the underlying thesis.

Looking Ahead: Next Ex-Dividend Catalysts

Of the 15 names in this calendar, six companies (PFE, VZ, T, BMY, USB, CVX) are scheduled to declare their next quarterly dividend in mid-to-late July 2026, with corresponding ex-dates expected in early-to-mid August. Investors building positions around the current ex-date should already be researching whether the next declared dividend is expected to hold flat, increase, or signal a warning. For pharmaceutical names (PFE, BMY, JNJ, MRK, GILD), Q2 2026 earnings in late July will be the most important catalyst — a dividend cut alongside weak earnings is the most common failure mode for high-yield equity names, and a single surprise cut typically causes a 10-20% share price re-rating within 48 hours.

Banking and energy names (WFC, USB, XOM, CVX) generally operate under regulatory capital constraints that cap dividend growth rates, so for these names the announcement is more likely to be a confirmation of an already-published quarterly figure than a surprise. Consumer staples (PEP, PG, KO) have historically been among the most reliable dividend growers in the table — expect mid-single-digit annual increases at the next declaration for all three. Real-estate investment trusts and telecom infrastructure providers (T, VZ) are still working through 2024-2025 deleveraging, so dividend stability is the more relevant metric than growth for these positions in the near term. KabuWire will publish the next iteration of this weekly calendar as the ex-dates approach.

This dividend calendar is for informational purposes only and does not constitute investment advice. Dividend payments and dates are subject to change at company discretion. Investors should verify all information independently and consult with financial advisors before making investment decisions. Past dividend performance does not guarantee future payments.